Researchers found that aggressive breast cancers store glycogen in very large amounts, offering an explanation of how cells can change their function to evade treatment, grow and spread. Targeting an enzyme involved in this process could potentially treat or prevent metastases.
Read moreA novel anticancer molecule created by researchers showed therapeutic activity in preclinical models of various cancer types.
Read moreTwo new studies report progress in using stem cells to develop new therapies for Pelizaeus-Merzbacher disease (PMD), a rare genetic condition affecting boys that can be fatal before 10 years of age.
Read moreRoutine testing for bowel cancer should not be recommended for everyone aged 50-79 years because, for those at very low risk, the benefit is small and uncertain and there are potential harms, say a panel of international experts.
Read moreA new 3D structure for growing cell cultures could enable doctors to test medications on model tumors grown from a patient's own cells, according to a team of engineers and cancer researchers.
Read moreA research study has identified a novel prostate cancer gene fusion involving the KLK4 protein coding gene and KLKP1 pseudogene. This unique biomarker can be detected in the urine samples of patients with prostate cancer, offering a non-invasive means of detection.
Read moreA new study finds that a form of immunotherapy used to treat the blood cancer leukemia may be effective in treating other kinds of cancer as well.
Read moreImmune therapy added to chemotherapy improves pathological complete response in patients with early triple negative breast cancer, according to new results from the KEYNOTE-522 trial. Interim results from the study, which is the first phase III trial of immunotherapy in early breast cancer, also indicated an improvement in event-free survival.
Read moreFor the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial. This marks a significant advance for prostate cancer treatment, which has lagged behind other common cancers with regard to precision therapy, now the standard of care in breast, ovarian and lung cancers.
Read moreIn the prospective TAILORx trial, 93% of women with hormone-sensitive, HER2-negative, axillary node-negative breast cancer and a high Recurrence Score 26-100 were estimated to be cancer-free at five years. This outcome was much better than expected with endocrine therapy alone. The finding adds to limited data on outcomes with a high RS of 26-100, treated with taxane and/or anthracycline-containing chemotherapy plus endocrine therapy. It adds to the body of evidence supporting use of the RS.
Read more